Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease
Sponsor: Arrowhead Pharmaceuticals
Summary
Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of ARO-MAPT-SC compared to placebo in adult healthy volunteers and in participants with early Alzheimer's disease (AD), defined as mild cognitive impairment due to AD and mild AD dementia.
Official title: A Phase 1/2a Placebo-Controlled Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
112
Start Date
2025-11-18
Completion Date
2027-06
Last Updated
2025-12-11
Healthy Volunteers
Yes
Interventions
ARO-MAPT-SC
• single or multiple doses of ARO-MAPT-SC by subcutaneous (SC) injection
Placebo
• calculated volume to match active treatment by SC administration
Locations (1)
Research Site 1
Grafton, Auckland, New Zealand